Immunization of *Litopenaeus vannamei* shrimp against white spot syndrome virus (WSSV) by gamma-irradiated WSSV plus *Vibrio paraheomolyticus*

Motamedi-Sedeh F*, Afsharnasab M², Heidarieh M¹

¹Nuclear Science and Technology Research Institute, Tehran, Iran.
²Iranian Fisheries Science Research Institute, Tehran, Iran.

**ABSTRACT**

**Introduction:** White spot syndrome virus (WSSV) is one of the most deadly infectious pathogens of the shrimp culture industry. Neither effective vaccines nor efficient treatments are currently available for this disease. *Vibrio* species are well known dominant bacterial pathogens in the shrimp ponds. As facultative pathogenic bacteria, it is possible that *Vibrio* spp. along with WSSV to co-infect the shrimp species such as *Litopenaeus vannamei*. The aim of this study was to investigate the co-administration of gamma-irradiated *Vibrio paraheomolyticus* as a kind of probiotic and immune-stimulator with gamma-irradiated and inactivated WSSV as an intramuscular vaccine for protection of *L. vannamei* against WSSV infection. **Methods:** WSSV was isolated from the infected shrimp samples and multiplied in *Astacus leptodactylus* crayfish. Titration of WSSV was obtained in post-larvae as $10^{3.4}$ LD$_{50}$/ml. The virus was irradiated where D$_{10}$ value and optimum dose of gamma ray were calculated to be 2.56 and 15 kGy, respectively. The gamma-irradiated WSSV samples, named GI-WSSV were used as a vaccine to immunize *L. vannamei* shrimps. The freeze-dried *V. paraheomolyticus* cultures, inactivated by gamma ray (8 kGy) were named GI-V.P and used as a probiotic. **Results:** Protective dose50 was calculated as 5.61 and 7.94 for the shrimp groups which were vaccinated by GI–WSSV vaccine and GI-WSSV vaccine + GI-V.P, respectively. Calculated RPS values were 73.3%, 86.66% and 26.66% for the GI-WSSV vaccine, GI-WSSV + GI-V.P and isolated probiotic groups, respectively. Significant differences in cumulative mortalities were observed between the vaccination groups and the positive control group (P < 0.05). No significant difference was observed in cumulative mortalities between the two vaccination groups (P > 0.05). **Conclusion:** GI-WSSV vaccine can induce immune responses in shrimps infected with WSSV and probiotic GI-V.P enhances these responses.

**KEYWORDS:** White Spot Syndrome Virus (WSSV), Shrimp, Gamma Irradiation, *Vibrio paraheomolyticus*, Probiotic.

**INTRODUCTION**

White spot syndrome virus (WSSV) was discovered in Southeast Asia in 1992 and is currently the most important viral pathogen that affects shrimp stocks throughout the world. This virus causes up to 100% mortality within 7 to 10 days in commercial shrimp farms, inflicting large economic losses to the shrimp farming industry. WSSV belongs to *Nimaviridae* family and *Whispovirus* genus with a double-stranded DNA genome [1, 2] and is considered among the greatest threats to the worldwide shrimp aquaculture industry [3]. Vaccination with immune stimulators which are widely advocated to prevent infections are limited; however, the presence of virus inhibiting proteins and specific up-regulation of genes upon viral infection, have been demonstrated [6-9]. Furthermore, immune stimulations and vaccinations with inactivated *Vibrio* spp. protect shrimps against vibriosis and WSSV [10-12]. *Vibrio* species are well known in penaeid shrimp cultures as the causative agents of vibriosis. This important bacterial disease can be caused by *V. anguillarum, V. alginolyticus, V.*
V. parahaemolyticus, V. harveyi and V. campbellii, in grow-out cultures and hatcheries [13, 14]. As a known facultative pathogenic bacterium, it is possible that Vibrio spp. and WSSV to co-infect shrimps regularly in the field. Vibriosis usually occurs during the first month of the shrimp cultivation in the field and may cause more than 50% mortality. So far, it has been unclear whether Vibrio spp. is an opportunistic or a primary pathogen. In this investigation, gamma-irradiated V. parahaemolyticus as a probiotic and immune-stimulator, was co-administrated with gamma-irradiated and inactivated WSSV as an intramuscular vaccine for protection of L. vannamei against WSSV.

MATERIALS and METHODS

Virus stock
The infected shrimp samples with symptoms of WSSV infection were collected from a shrimp farm in Bushehr province of Iran and WSSV infection was confirmed by nested PCR according to guideline of IQ 2000 diagnostic kit (Gene Reach Biotechnology Corp., Taiwan) [15, 16]. The infected gill, stomach, muscle and hepato-pancreas tissues of the shrimp samples were homogenized and used for multiplication of WSSV in Astacus leptodactylus crayfish, following filtration through 0.45 µm filter. The WSSV stock isolated from Iran is called WSSV/IRN/1/2010 [17-21].

Gamma irradiation and inactivation of V. parahaemolyticus and WSSV
V. parahaemolyticus (ATCC: 17802) was a gift from Veterinary Faculty of Tehran University. The bacterium was cultured on tryptic soy broth (TSB) with 3% NaCl, aliquoted in 5 ml vials. The bacteria samples were lyophilized then irradiated by Gamma cell-Co60 source (MDS Nordian, Canada) with dose rate and activity of 4.8 Gy/sec and 20469 Ci, respectively. Different doses of gamma rays, i.e. 2, 4, 6, 8 and 10 kGy were used. The bacterial loads of the irradiated and unirradiated V. parahaemolyticus were determined as colony forming unit per milliliter (CFU/ml) and dose/ survival curve of bacterial inactivation was plotted by Origin6.1 software. The optimum dose of inactivation and D10 value (a dose of gamma irradiation that can decrease one logarithmic cycle of microorganism population) were calculated according to the curve. The gamma irradiated V. parahaemolyticus (GI-V.P) was used as a probiotic to stimulate the immune system. The WSSV viral stock was aliquotted as 5 ml samples which were irradiated by Gamma cell-Co60 source (MDS Nordian) with dose rate and activity of 4.8 Gy/sec and 20469 Ci, respectively. Different doses of gamma rays, i.e. 1, 3, 5, 10, 20, 25, 30 and 35 kGy were used for irradiation of the frozen viral samples held on dry ice, and three viral samples were subjected to each irradiation gamma dose [21]. The dose/survival curve was plotted using Origin software, and D10 value and optimum doses of gamma ray for viral inactivation were obtained according to the dose/survival curve. At the end, 100 ml of WSSV stock was irradiated with the optimum dose of gamma ray and formulated as the gamma-irradiated (GI-WSSV) vaccine.

In vivo virus titration
The virus titrations of the irradiated and unirradiated samples were conducted on Penaeus semisulcatus shrimps [20]. All shrimp in the negative control group survived, whereas mortality due to WSSV infection was observed in all groups with virus dilution during one week. All the dead shrimps were examined for WSSV by nested PCR [22]. Lethal dose 50 (LD50) was calculated by Karber method [23].

Safety test
The infectivity of the irradiated and inactivated virus samples by the optimum dose of gamma ray was determined by inoculating P. semisulcatus post-larvae (weighing 1 g) shrimp via immersion method at 20° C for 7 days which were then sub-cultured on fresh post-larvae 4 times during 4 weeks. The safety test was also carried out for irradiated V. parahaemolyticus by sub-culturing on Tiosulfat citrate bile salt sucrose agar (TCBS) three times.

Administration of GI-WSSV vaccine and GI-V.P
Juvenile Litopenaeus vannamei shrimps (weighing 10-15 g), were harvested from a shrimp farm which implements biosecurity measures routinely with no history of WSSV outbreak. Some of the shrimp samples were analyzed randomly by PCR to confirm the absence of WSSV contamination. Approximately, 220 shrimps were selected in 11 groups (n = 20) and kept in aquariums with flow-through seawater at 25-27° C and fed at 5% of body weight per day with commercial crumbled feed before and during the experiment. The samples in groups 1-4 were injected with 50 μl of 4 dilutions of GI-WSSV vaccine (1, 1/2, 1/4 and 1/8) intramuscularly in the 4th or 5th abdominal segments, respectively. The samples in groups 5-8 were co-administrated with GI-WSSV vaccine (the same above dilutions) along with GI-V.P (3×10^7/20 μl) intramuscularly. The vaccination was followed after a 2-week-interval with the same doses as a booster. On day 10 post immunization (dpi), each animal in groups 1-8 was intramuscularly challenged by injection of live WSSV (100 LD50/50 μl). The groups 9, 10 and 11 were listed as negative control (injected with phosphate buffer saline (PBS)), virus-positive control (injected with live WSSV) and bacteria-positive control (injected with GI-V.P (3×10^7/20 μl)), respectively. The mortality rate was recorded during 10 days in all groups, and protective dose50 (PD50) was calculated for both kinds of vaccines (i.e. GI-WSSV alone and GI-WSSV along with GI-V.P) by Reed and Muench method [24, 25]. The relative percent survival (RPS) values were also calculated according to Amend, 1981 [26].

Statistical Analysis
Analysis of variance (One way ANOVA) was carried out by SPSS16.0 software followed by Duncan’s multiple range test. The differences were considered to be statistically significant at p < 0.05 level.

RESULTS

V. parahaemolyticus (ATCC: 17802) was cultured on TCBS agar and the bacterial load of the irradiated and unirradiated samples were determined as CFU/ml. The optimum dose of gamma ray for inactivation of the bacteria and D10 value according to the dose/response curve were obtained to be 0.98 and 9.98 kGy, respectively (Fig.1). The frozen V. parahaemolyticus was inactivated by 10 kGy of gamma radiation and the gamma-irradiated V. parahaemolyticus (GI-V.P) was used as a probiotic to enhance the shrimp’s immune responses. The WSSV infection was confirmed by clinical signs and nested PCR in the infected shrimp samples which were collected from the farm. The PCR results for the tissues and haemolymph of WSSV-infected crayfish were positive (Fig. 2).
The LD50 of the live virus stock (WSSV/IRN/1/2010) was calculated at $10^{5.4}$/ml by the Karber formula [23, 27]. D$_{10}$ value and the optimum dose of gamma ray for viral inactivation were calculated according to the dose/response curve for the irradiated and unirradiated viral samples at 2.56 and 15 kGy, respectively (Fig. 3).

The viral load (LD50/ml) also decreased gradually with an increase in gamma irradiation (Table 1). Amongst moribund shrimp post-larvae (all the groups), the PCR products indicated high WSSV DNA load and negative PCR results were detected from the negative control shrimp samples (Fig. 4).

The safety test after 4 blind passages of GI-WSSV on P. semisulcatus post-larvae (weighing 1 g) via immersion method was successful when no mortality was observed after inactivation by 15 kGy of gamma ray applied to the WSSV/IRN/1/2010 titrating at $10^{3.8}$ LD$_{50}$/ml.

PD50 indicated the number of protective dose in a vaccine estimated from the resistance to live virus challenge in animal groups receiving different amounts of vaccine and calculated by the Reed and Muench method. The PD50 for the GI-WSSV vaccine and GI-WSSV + GI-V.P were obtained at 5.61 and 7.94, respectively. Therefore, GI-V.P enhanced the immune responses of the shrimps when it was co-administered with GI-WSSV vaccine.

The cumulative mortalities on the 10th dpi in the groups vaccinated intramuscularly with GI-WSSV vaccine alone, GI-WSSV + GI-V.P, bacteria-positive control (GI-V.P alone), negative control (PBS injection) and virus-positive control were measured as 20%, 10%, 55%, 0% and 75%, respectively. The calculated RPS values were 73.3%, 86.66% and 26.66% for the GI-WSSV vaccine, GI-WSSV + GI-V.P and GI-V.P isolated groups which were vaccinated by injection, respectively (Table 2).

In cumulative mortalities were observed significant differences between both vaccination groups (i.e. GI-WSSV and GI-WSSV+ GI-V.P) and the positive control group (P < 0.05). No significant difference in cumulative mortalities was observed between the two vaccination groups (P > 0.05). As there is no significant difference between the vaccinated groups with and without GI-V.P, it can be suggested that GI-WSSV vaccine can induce immune responses in shrimps infected with WSSV while probiotic (GI-V.P) can enhance these responses although a significant effect was not detected between both vaccination groups (i.e. GI-WSSV and GI-WSSV+ GI-V.P) and the positive control group (P < 0.05). Meanwhile, no significant difference in cumulative mortalities was observed between the two vaccination groups (P > 0.05). As there is no significant difference between the vaccinated groups with and without GI-V.P, it can be suggested that GI-WSSV vaccine can induce immune responses in shrimps infected with WSSV while probiotic (GI-V.P) can enhance these responses although a significant effect was not detected.
Table 1. Virus titers for irradiated and naive WSV/IRN/1/2010 preparations

<table>
<thead>
<tr>
<th>Dose of gamma irradiation (kGy)</th>
<th>0</th>
<th>1</th>
<th>3</th>
<th>5</th>
<th>10</th>
<th>20</th>
<th>25</th>
<th>30</th>
<th>35</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virus titration (LD_{50}/ml)</td>
<td>10^{5.4}</td>
<td>10^{5.3}</td>
<td>10^{3.6}</td>
<td>10^{2.4}</td>
<td>10^{1.7}</td>
<td>10^{1.5}</td>
<td>10^{1.5}</td>
<td>10^{1.5}</td>
<td>10^{1.5}</td>
</tr>
</tbody>
</table>

Table 2. Resistance against experimental WSSV/IRN/1/2010 infection in shrimps vaccinated with GI-WSSV vaccine plus GI-V.P

<table>
<thead>
<tr>
<th>Vaccine groups</th>
<th>Dead/tested</th>
<th>Route of administration: Injection (IM)</th>
<th>Mortality (%)</th>
<th>RPS (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI-WSSV vaccine</td>
<td>4/20</td>
<td>Injection (IM)</td>
<td>20</td>
<td>73.33</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>GI-WSSV vaccine + GI-V.P</td>
<td>2/20</td>
<td>Injection (IM)</td>
<td>10</td>
<td>86.66</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>GI-V.P (probiotic)</td>
<td>11/20</td>
<td>Injection (IM)</td>
<td>55</td>
<td>26.66</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Virus positive control</td>
<td>15/20</td>
<td>Injection (IM)</td>
<td>75</td>
<td>0</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Negative control</td>
<td>0/20</td>
<td>Injection (IM)</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION

Ionizing radiation is a highly reliable procedure in which electromagnetic radiation such as gamma rays, emitted from Cobalt 60 or Cesium 137 isotopes, is used for inactivation of microorganisms such as viruses, with the advantage of minimal molecular changes to the viral proteins and structures [28]. Virus inactivation by gamma and electron irradiations follows physical laws, including an exponential law that means an organism will probably survive irrespective of the irradiation dose. Sterility assurance level or SAL is the value of such a probability. SAL is in general a value of 10^{-6} (a one in a million chance of having live microorganisms) [29]. When inactivated vaccine are going to be prepared, the most important parameter is the minimum inactivation endpoint which is dependent on parameters such as the inactivation rate, dose of irradiation and virus titer per volume unit [27]. Ionizing radiations such as gamma rays can damage the molecular structure of viral nucleic acids that cause virucidal effect [28, 30, 31]. A great deal of advanced research has recently been devoted to inactivation of viruses, bacteria and parasites by ionizing radiation. For instance, we have previously shown that gamma-irradiated vaccine against FMDV type O/IRN/1/2007 and FMDV type A/87/IRN could induce protective immune responses in mice and guinea pigs [32]. Furthermore, Lombardo and Smolko [33] have studied gamma-irradiated FMDV with unaltered antigenicity as an inactivated vaccine. In addition, the ability of gamma-irradiated and inactivated influenza virus to induce both a strong humoral and a potent T-cell response should encourage the consideration of this technique in the search for a promising vaccine against other viral diseases [34]. Studies about the shrimp immune responses against the viral infections are limited, however the presence of virus inhibiting proteins and specific up-regulation of shrimp genes upon viral infections have been demonstrated [10, 11, 35]. In vivo experiments with Penaeus japonicus have shown the presence of a quasi-immune response when the survivors of both the natural and the experimental WSSV infections were re-challenged with WSSV [4]. Recent studies have shown that plasma from the surviving infected shrimps could neutralize WSSV, 20 to 60 days after the infection [36]. These outcomes suggest that a form of adaptive immune response could exist in shrimps [19]. Moreover, a study on the antiviral immunity in crustaceans has shown the induction of shrimp genes associated with its ability to survive the viral infections. However, it is not clear which of these shrimp genes would lead to the production of the antiviral substances [37]. Phouc et al. have reported the synergistic effect...
of WSSV and V. campbellii on the development of the disease in specific pathogen-free L. vannamei shrimp [12]. According to this study, GI-WSSV can induce immune responses in shrimp infected with WSSV, and probiotic (GI-V.P) can enhance these responses. This remark lightens up the way for designing practical strategies to control WSSV infections as well as other invertebrate pathogens. Furthermore, the co-administration of GI-V.P as a probiotic could enhance the immunity against WSSV. Therefore, following more practical routes of vaccine administration such as bath-immersion or oral vaccination might lead to a highly promising vista of the next research domains in this field. On this regard, studies on the post-larvae vaccination in shrimp hatcheries, vaccine shell life and duration of the immunity against WSSV after the vaccination are highly suggested.

ACKNOWLEDGEMENT

The authors express their gratitude to the Research and Technology Deputy of the Nuclear Science and Technology Research Institute and Research Deputy of the Fishery Science and Research Institute of Iran and Shrimp Research School. We also express our gratitude to Roshan Zamir, MA, for English language editing.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES